The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Ulrike NitzOleg GluzHans H KreipeMatthias ChristgenSherko KuemmelFrederick L BaehnerSteven ShakBahriye AktasMichael BraunKerstin Lüdtke-HeckenkampHelmut ForstbauerEva-Maria GrischkeBenno NudingMaren DarsowClaudia SchumacherKatja KraussWolfram MalterMarc ThillMathias WarmRachel WuerstleinRonald E KatesNadia HarbeckPublished in: Therapeutic advances in medical oncology (2020)
NCT01779206.